All In Biotech

Drug Trial Radar · NCT00226499

Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox

Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine

Last checked: Nov 20, 2026Latest source record: Sep 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,803 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,803

Actual

Start

Sep 1, 2005

Primary completion

Oct 12, 2006

Study completion Oct 12, 2006

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 27, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 11 months, up to 22 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An observer-blind study to evaluate GlaxoSmithKline Biologicals' live attenuated varicella vaccine and GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella vaccine in the prevention of varicella disease in children. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Conditions

  • Varicella
  • Chickenpox Vaccines

Interventions

  • Priorix-tetra™Biological

    2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group

  • Priorix™Biological

    2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group

  • Varilrix™Biological

    1 dose administered subcutaneously at Day 42 to subjects in OKAH Group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase A: Number of Subjects With Confirmed Varicella CaseTime frame: From 42 days post dose 2 until the end of Phase A

Locations

104 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    Chomutov, Czechia

  • GSK Investigational Site

    Děčín, Czechia

  • GSK Investigational Site

    Havlíčkův Brod, Czechia

  • GSK Investigational Site

    Hradec Králové, Czechia

  • GSK Investigational Site

    Humpolec, Czechia

  • GSK Investigational Site

    Jindřichův Hradec, Czechia

  • GSK Investigational Site

    Kolín, Czechia

  • GSK Investigational Site

    Liberec, Czechia

  • GSK Investigational Site

    Moravská Ostrava, Czechia

  • GSK Investigational Site

    Náchod, Czechia

  • GSK Investigational Site

    Ostrava, Czechia

  • GSK Investigational Site

    Pardubice, Czechia

  • GSK Investigational Site

    Pilsen, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Znojmo, Czechia

  • GSK Investigational Site

    Arta, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Giannitsá, Greece

  • GSK Investigational Site

    Karditsa, Greece

  • GSK Investigational Site

    Komotini, Greece

  • GSK Investigational Site

    Ptolemaida, Greece

  • GSK Investigational Site

    Thessaloniki, Greece

  • GSK Investigational Site

    Tripoli, Greece

  • GSK Investigational Site

    Véria, Greece

  • GSK Investigational Site

    Quarto (NA), Campania, Italy

  • GSK Investigational Site

    Ferrara, Emilia-Romagna, Italy

  • GSK Investigational Site

    Udine, Friuli Venezia Giulia, Italy

  • GSK Investigational Site

    Genoa, Liguria, Italy

  • GSK Investigational Site

    Milan, Lombardy, Italy

  • GSK Investigational Site

    Novara, Piedmont, Italy

  • GSK Investigational Site

    Alghero (SS), Sardinia, Italy

  • GSK Investigational Site

    Ozieri (SS), Sardinia, Italy

  • GSK Investigational Site

    Florence, Tuscany, Italy

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.